image description

Tag: PhD

Lupus Research Alliance Awards Lupus Insight Prize to Two Trailblazers in CAR T Cell Therapy

SAN FRANCISCO, CA, June 20, 2024 — The Lupus Research Alliance (LRA) announced the recipients of the 2024 Lupus Insight Prize to Marko Radic, Ph.D., The University of Tennessee Health Science Center, and Georg Schett, M.D., Friedrich-Alexander-Universität Erlangen-Nürnberg, for their groundbreaking discoveries in utilizing CAR T cell therapy to potentially revolutionize lupus treatment. Drs. Radic […] Read More

LRA Announces Partners on the First Anniversary of the Lupus Landmark Study

April 11, 2024 The Lupus Research Alliance (LRA) and its clinical research affiliate Lupus Therapeutics (LT) are pleased to announce the group of industry partners working together on the implementation of the Lupus Nexus. The Lupus Nexus, one of LRA’s most ambitious and groundbreaking endeavors, is a first-of-its-kind lupus registry, biorepository, and data exchange platform […] Read More

Recent Discoveries Shedding Light on Why Women Are at a Greater Risk for Lupus

March 20, 2024 Lupus is a complex autoimmune disease affecting millions worldwide with a staggering gender imbalance — about 9 of 10 people with lupus are women. Underlying biological, hormonal, or environmental factors likely contribute to why lupus affects females more often. Understanding why women are at greater risk for lupus could unlock novel treatments […] Read More

To Increase Diversity in Lupus Clinical Research, Project CHANGE Launches Pilot Programs in Atlanta, Nashville, and Philadelphia

NEW YORK, NY, June 29, 2023 — The clinical research affiliate of the Lupus Research Alliance, Lupus Therapeutics, launched three pilot research initiatives for Project CHANGE, a community-driven approach to address systemic challenges contributing to the underrepresentation of people of color, particularly Black people, in lupus clinical trials. Emory University in Atlanta, Vanderbilt University in Nashville, […] Read More

Lupus Research Alliance Appoints New Executive Vice President of Clinical Research Affiliate Lupus Therapeutics

NEW YORK, NY. January 17, 2023— The Lupus Research Alliance (LRA) announced the appointment of Stacie J. Bell, PhD as Executive Vice President to lead the organization’s clinical research affiliate Lupus Therapeutics (LT). Dr. Bell comes to Lupus Therapeutics with 25+ years of experience in discovery research, clinical development, and patient engagement in the biopharmaceutical […] Read More

Saluting Women Shaping LRA’s Strategic Scientific Direction

March 8, 2022 In honor of Women’s History Month, the LRA is saluting the three exceptional women who serve on our Scientific Advisory Board. Each is a stand-out in lupus research discovery: Mary Collins, PhD, Instructor at Harvard Medical School;  Judith James, MD, PhD, Chair of the Arthritis and Clinical Immunology Program and Lou Kerr […] Read More

Lupus Research Alliance Applauds U.S. FDA Approval of AstraZeneca’s anifrolumab-fnia (Saphnelo™) for Systemic Lupus Erythematosus (SLE)

  First in New Class of Drugs in More than a Decade for SLE Targeting Type 1 Interferons NEW YORK, NY. August 2, 2021. The Lupus Research Alliance (LRA) is particularly excited about the U.S. Food and Drug Administration (FDA) approval of anifrolumab-fnia (Saphnelo™), a first-in-class type I interferon receptor antagonist indicated for adults with […] Read More

The LRA’s Forum for Discovery: Sharing the Latest News in Lupus Research

The Lupus Research Alliance (LRA) held our annual scientific conference, the Forum for Discovery, online in true 2020 fashion. More than 150 funded investigators, scientific advisors, and partners from the pharmaceutical and biotech industries logged on from their computers around the world to hear about new discoveries from LRA-funded researchers. LRA President Ken Farber emphasized […] Read More

LRA-Supported Study Discovers How Harmful Immune Cells Develop

August 17, 2020 In a new study published in the journal Immunity, Lupus Research Alliance-funded researcher Dr. Boris Reizis and his colleagues identified conditions under which immune cells called B cells begin to attack healthy genetic material (DNA). Dr. Reizis’ findings highlight the potential of drugs such as anifrolumab and BIIB-059 as potential treatments for […] Read More